Expression and clinical significance of BRMS1 and Survivin in breast cancer

WANG Dayong

doi:10.3969/j.issn.1002-7386.2014.03.007

Abstract：Objective To investigate the expression and clinical significance of BRMS1 and Survivin in breast cancer,and to explore the correlation between them and their effects on the pathogenesis ,development,metastasis and prognosis of breast cancer.Methods The expression levels of BRMS1 and Survivin were detected by immunohistochemistry in 160 cases of breast cancer,70 cases of mammary glands benign proliferative lesions and 40 cases of normal tissues adjacent to breast cancer.The data was analyzed together with clinical pathological parameters .Results The positive expression rates of BRMS1in breast cancer, mammary glands benign proliferative lesions and normal tissues adjacent to breast cancer were 34.4%,81.4%,95.0%,respectively,the positive expression rates of BRMS1 in breast cancer were significantly decreased ,as compared with those in mammary glands benign proliferative lesions and normal tissues adjacent to breast cancer ( P <0.05).However the positive expression rates of Survivin in breast cancer ,mammary glands benign proliferative lesions and normal tissues adjacent to breast cancer were 78.8%,17.1%,0,respectively,the positive expression rates of Survivin breast cancer were significantly increased,as compared with those in mammary glands benign proliferative lesions and normal tissues adjacent to breast cancer ( P <0.05).The abnormal expression of BRMS1 and Survivin in breast cancer tissue was correlated to TNM clinical stage and lymph node metastasis .Survivin was also related to histological grade .The abnormal expression of BRMS1 and Survivin in breast cancer tissue was not related to patient's age and tumor's size,but the expression of BRMS1 was negatively correlated with that of Survivin .Conclusion BRMS1 and Survivin play an important role in the carcinogenesis , development,metastasis and prognosis of breast cancer ,which can be used as the markers in diagnosis and prognosis evaluation of breast cancer.